BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 1309944)

  • 1. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Overgaard K; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause.
    Polatti F; Capuzzo E; Viazzo F; Colleoni R; Abbiati I; Nappi RE
    Acta Obstet Gynecol Scand; 1999 Jan; 78(1):49-53. PubMed ID: 9926892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Riis BJ; Christiansen C
    Eur J Clin Invest; 1991 Dec; 21(6):601-7. PubMed ID: 1838079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
    Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyproterone acetate, an alternative gestagen in postmenopausal oestrogen/gestagen therapy.
    Riis BJ; Jensen J; Christiansen C
    Clin Endocrinol (Oxf); 1987 Mar; 26(3):327-34. PubMed ID: 2820619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
    Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women.
    Christiansen C; Riis BJ
    J Clin Endocrinol Metab; 1990 Oct; 71(4):836-41. PubMed ID: 2205624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
    Bunyavejchevin S; Limpaphayom KK
    J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A one-year prospective study of disodium etidronate versus 17 beta estradiol in the prevention of postmenopausal osteoporosis].
    Chaouat D; Belange G; Danan S; De Vernejoul MC; Faures Quenet B; Chaouat Y
    Rev Rhum Ed Fr; 1993 May; 60(5):353-8. PubMed ID: 8167642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-progestogen replacement therapy in postmenopausal women--is 1 mg estradiolvalerate sufficient to maintain axial trabecular bone density?
    Dören M; Schneider HP
    Int J Clin Pharmacol Ther; 1994 May; 32(5):254-8. PubMed ID: 7921520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.
    Prince RL; Smith M; Dick IM; Price RI; Webb PG; Henderson NK; Harris MM
    N Engl J Med; 1991 Oct; 325(17):1189-95. PubMed ID: 1922205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The avoidance of early postmenopausal bone substance losses by transdermal estrogen substitution].
    Ringe JD; Meiss F
    Dtsch Med Wochenschr; 1993 May; 118(21):769-74. PubMed ID: 8504712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
    Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.